Clinical Impact of New NAFLD/NASH Data From San Francisco 2018

November 9-13, 2018; San Francisco, California
Expert faculty summarize key NAFLD/NASH studies from this important annual conference. Use these slides to review data on noninvasive screening, clinical outcomes, emerging treatments.
Ira M. Jacobson, MD
Philip N. Newsome, PhD, FRCPE
Format: Microsoft PowerPoint (.ppt)
File Size: 421 KB
Released: December 3, 2018

Acknowledgements

Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Short CME/CE-certified video from CCO: Expert review of case studies improving evaluation and diagnosis of patients with hATTR.

Jonathan Mazurek, MD Aaron Walfish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 21, 2020 Expired: September 20, 2021

Slides from CCO: Experts discuss case studies for improving diagnosis and evaluation of Hereditary Transthyretin Amyloidosis (hATTR).

Jonathan Mazurek, MD Aaron Walfish, MD Released: September 21, 2020

Slides from CCO: Expert recommendations for improving diagnosis and evaluation of Hereditary Transthyretin Amyloidosis (hATTR).

Released: September 18, 2020

Short CME/CE-certified audio activity with slides from CCO on improving evaluation and diagnosis of patients with hereditary transthyretin amyloidosis (hATTR)

Jonathan Mazurek, MD Aaron Walfish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 18, 2020 Expired: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue